Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

According to Reuters, the grocery retailer notified Express Scripts in September 2022 of its plan to terminate the pharmacy provider agreement for commercial customers because of an “unsustainable” ...

Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.” While we acknowledge the potential ...

True, AbbVie's most important drug through most of those years, rheumatoid arthritis medicine Humira, is now out of patent exclusivity. However, the company is handling that loss just fine.

AbbVie Inc (NYSE:ABBV) delivered full-year adjusted earnings per share of $10.12, exceeding initial guidance by $0.49. Total net revenues were $56.3 billion, surpassing initial guidance by more than ...

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar; ...

These strong results demonstrate AbbVie's resilience in navigating the transition away from its former flagship product, as Humira sales decreased by 49% to $1.68 billion in the fourth quarter.

AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are ...

AbbVie demonstrated solid performance in Q4 2024, with its ex-HUMIRA platform contributing significantly to growth. The platform reported an 18% increase in full-year sales, accelerating to 22% in the ...